Skip to main content
Elsevier

Animal Models of Disease Part E

  • 1st Edition, Volume 203 - February 27, 2026
  • Latest edition
  • Editors: Lorenzo Galluzzi, Jose Manuel Bravo-San Pedro, Fernando Aranda Vega
  • Language: English

Animal Models of Disease, Part E, Volume 203 in the Methods in Cell Biology series, presents significant advancements in understanding disease mechanisms through animal models… Read more

Description

Animal Models of Disease, Part E, Volume 203 in the Methods in Cell Biology series, presents significant advancements in understanding disease mechanisms through animal models. The book features chapters on timely topics such as characterizing tumor-infiltrating group 1 innate lymphoid cells in PyMT breast tumors and using zebrafish to unravel the molecular mechanisms of Alzheimer’s disease. The book also covers colitis mouse models and appropriate models for studying diabetes pathophysiology, demonstrating its comprehensive approach to current research.

Additional sections cover evaluating polyglutamine protein aggregation in transgenic Caenorhabditis elegans models of Huntington's disease and studying tumor responses to radioimmunotherapy in ovarian cancer models. It also highlights the antimicrobial regime for gut microbiota depletion in mice and the biodistribution of metallic nanoparticles for lymphoma studies. This book is an essential resource for researchers seeking to explore disease mechanisms and therapeutic approaches through animal models.

Key features

  • Provides the latest information on cancer research
  • Offers outstanding and original reviews on a range of cancer research topics
  • Serves as an indispensable reference for researchers and students alike

Readership

Researchers, Academic Institutions, Medical and Healthcare Professionals

Table of contents

1. Establishment single lung tumors through orthotopic injection

Beñat Picabea, Céline Clémenson, Mirari Echepare, Cristina Viu-Idocin, Ane Álava,
Estefanía Rodríguez, Michele Mondini, Karmele Valencia

2. Intracardiac injection as a metastatic model in lung cancerEstablishment single lung tumors through orthotopic injection

Mirari Echepare, Beñat Picabea, Cristina Viu-Idocin, Ane Álava, Estefanía Rodríguez,
Karmele Valencia

3. Adeno-associated viral vector administration to the inner ear and phenotype evaluation in a mouse model of hearing loss

Sergio Isola and Carmen Unzu

4. DiLiCre2.0 mouse model: An advanced genome-editing tool to induce mutagenesis in vivo with high spatio-temporal resolution

Miguel Vizosoa

5. A new inducible mouse model of FH loss

Vincent Zecchini, Chrysanthi Moschandrea, Farina Schneider, and Christian Frezza

6. Monitoring neuronal mitophagy and locomotion deficits in a C. elegans model of Alzheimer's disease

Giorgos Garcia Niforos, Eleni Tsakiri, and Konstantinos Palikaras

7. Experimental models and methods for infected wound modeling with Staphylococcus aureus

Estela Pérez, Guillermo Landa, Isabel Bescós, Ignacio Ochoa, and Elena Tapia

8. Multiplex immunohistochemistry (IHC) profiling of murine tumour-infiltrating T cells

Erminia Romano, Caron Behan, Alexander Baker, Garry Ashton, and Jamie Honeychurch

9. Isolation of Regulatory T Cells from Healthy Murine Mammary Glands

D.Michael Mann, Hossein Ehsanbakhsh, and Paula D. Bos

10. Metastasis mouse model of breast cancer derived from Circulating Tumor Cells (CTCs) after primary orthotopic tumor resection.

Angela Pérez-Cervera, Haritz Moreno, Helena Villanueva, Angelina Zheleva, Beatriz Moreno, Fernando Lecanda, Fernando Pastor

11. Establishment of humanized patient-derived xenografts (PDXs) from primary human colorectal cancer tumors
Carmen Navarrete-Sirvent, Aurora Rivas-Crespo, María Teresa Sánchez-Montero,
Alejandra Díaz-Chacón, Regina Peña-Enríquez, Enrique Aranda, Antonio Rodríguez-Ariza, and Silvia Guil-Luna

  1. Modeling stress-induced proteinopathies in Caenorhabditis elegans

Elena Caldero-Escudero and Silvia Romero-Sanz

  1. Intravital imaging of mouse subcutaneous tumors placed in the ear for the study of immune cell interaction with blood vessels

Almudena Manzanal, Beatrice Pinci, Carlos Luri-Rey, Diana Alcobia, David Causapé, and
Álvaro Teijiera

  1. Induction of allergic dermatitis with dinitrofluorobenzene in Yama mice

Yusuke Yamada-Satchwell, Kyoko Yoshizaki, Masashi Sakurai, and Masahiro Morimoto

Product details

  • Edition: 1
  • Latest edition
  • Volume: 203
  • Published: February 27, 2026
  • Language: English

About the editors

LG

Lorenzo Galluzzi

Lorenzo Galluzzi is Assistant Professor of Cell Biology in Radiation Oncology at the Department of Radiation Oncology of the Weill Cornell Medical College, Honorary Assistant Professor Adjunct with the Department of Dermatology of the Yale School of Medicine, Honorary Associate Professor with the Faculty of Medicine of the University of Paris, and Faculty Member with the Graduate School of Biomedical Sciences and Biotechnology of the University of Ferrara, the Graduate School of Pharmacological Sciences of the University of Padova, and the Graduate School of Network Oncology and Precision Medicine of the University of Rome “La Sapienza”. Moreover, he is Associate Director of the European Academy for Tumor Immunology and Founding Member of the European Research Institute for Integrated Cellular Pathology. Galluzzi is best known for major experimental and conceptual contributions to the fields of cell death, autophagy, tumor metabolism and tumor immunology. He has published over 450 articles in international peer-reviewed journals and is the Editor-in-Chief of four journals: OncoImmunology (which he co-founded in 2011), International Review of Cell and Molecular Biology, Methods in Cell biology, and Molecular and Cellular Oncology (which he co-founded in 2013). Additionally, he serves as Founding Editor for Microbial Cell and Cell Stress, and Associate Editor for Cell Death and Disease, Pharmacological Research and iScience.
Affiliations and expertise
Assistant Professor of Cell Biology in Radiation Oncology, Department of Radiation Oncology, Weill Cornell Medical College, NY, USA

JB

Jose Manuel Bravo-San Pedro

Jose Manuel Bravo-San Pedro is currently a researcher at the Department of Physiology of the Complutense University of Madrid thanks to a Ramon y Cajal contract grant. He got his Ph.D. in biochemistry, cellular biology and genetics from the University of Extremadura (Caceres, Spain) in 2011, and he did a post-doctoral stage in the laboratory of Prof. Guido Kroemer. His main research interests have always been linked to autophagy, addressing this cellular process associated with neurodegenerative diseases or cancer and recently obesity and specifically related to problems in the correct functioning of the cilium. He is co-inventor of two patents and co-author of 110 publications indexed in PubMed in prestigious international journals, with h-index 45 and 23768 cites (Dec 2022).
Affiliations and expertise
Departamento de Fisiología, Facultad de Medicina, Universidad Complutense de Madrid, Madrid, Spain

FA

Fernando Aranda Vega

Fernando Aranda holds a BSc in Biology (2006) and Biochemistry (2007) from the University of Navarra. Then, he specialized in different strategies of Cancer Immunotherapy with a MSc in Biomedical Research (2008), and a PhD Degree (2012) from the University of Navarra (Pamplona) – Cima University of Navarra. More than 12 years in translational research focus on antitumor immune responses and Cancer Immunotherapy. Author of 64 publications indexed in PubMed in prestigious international journals, with h-index 30 and 4,296 cites (October 2022). He completed the Program of Sara Borrell (ISCIII) -competitive Postdoctoral contract- in the Group of Immune Receptors of the Innate and Adaptive System (IDIBAPS), Barcelona (2016-2018). Co-author of 1 invention patent: Composition based on the fibronectin domain A for the treatment of melanoma - WO/2011/101332. In 2012, Fernando Aranda obtained a Scientific Award, "Profesor Durantez" II Edición, for the best scientific article in Tumor Immunology by Fundación LAIR. Recently, Fernando Aranda awarded a competitive Research Fellow contract “Miguel Servet tipo I” by Instituto de Salud Carlos III, to continue his independent researcher career (IP) in cancer immunotherapy issues. Specifically, he is involved in Translational Immunotherapy of Peritoneal Carcinomatosis. Currently, Fernando Aranda leads a research group in cooperation with Dr. Pedro Berraondo.
Affiliations and expertise
Fernando Aranda Vega, CIMA Universidad de Navarra, Program of Immunology and Immunotherapy, Spain

View book on ScienceDirect

Read Animal Models of Disease Part E on ScienceDirect